Breast Cancer Clinical Trial

A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors

Summary

To assess the safety and tolerability at increasing dose levels of PF-06650808 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available
Previously treated metastatic triple negative breast cancer that expresses Notch3 with at least one measurable lesion
Adequate bone marrow, renal and liver function

Exclusion Criteria:

Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of starting study treatment
Patients with known symptomatic brain metastases requiring steroids
Prior treatment with a compound of the same mechanism

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

40

Study ID:

NCT02129205

Recruitment Status:

Terminated

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

Ronald Reagan UCLA Medical Center, Drug Information Center
Los Angeles California, 90095, United States
Ronald Reagan UCLA Medical Center
Los Angeles California, 90095, United States
UCLA Hematology/Oncology
Los Angeles California, 90095, United States
Westwood Bowyer Clinic
Los Angeles California, 90095, United States
Santa Monica - UCLA Medical Center & Orthopaedic Hospital
Santa Monica California, 90404, United States
UCLA Hematology/Oncology - Santa Monica
Santa Monica California, 90404, United States
The Ohio State University James Cancer Hospital
Columbus Ohio, 43210, United States
The OSU Investigational Drug Services
Columbus Ohio, 43210, United States
The OSU Stephanie Spielman Comprehensive Breast Center
Columbus Ohio, 43212, United States
The Ohio State University Martha Morehouse Medical Plaza
Columbus Ohio, 43221, United States
South Texas Accelerated Research Therapeutics, LLC (START)
San Antonio Texas, 78229, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

40

Study ID:

NCT02129205

Recruitment Status:

Terminated

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider